Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Argus Health
Johnson and Johnson
Accenture
UBS
Chubb
Express Scripts
Harvard Business School
Farmers Insurance

Generated: June 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,604,229

« Back to Dashboard

Which drugs does patent 5,604,229 protect, and when does it expire?

Patent 5,604,229 protects GILENYA and is included in one NDA.

Protection for GILENYA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twelve patent family members in twelve countries.
Summary for Patent: 5,604,229
Title: 2-amino-1,3-propanediol compound and immunosuppressant
Abstract:2-Amino-1,3-propanediol compounds of the formula (I) ##STR1## wherein R is an optionally substituted straight- or branched carbon chain, an optionally substituted aryl, an optionally substituted cycloalkyl or the like, and R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are the same or different and each is a hydrogen, an alkyl, an aralkyl, an acyl or an alkoxycarbonyl, pharmaceutically acceptable salts thereof and immunosuppressants comprising these compounds as active ingredients. The 2-amino-1,3-propanediol compounds of the present invention show immunosuppressive action and are useful for suppressing rejection in organ or bone marrow tranplantation, prevention and treatment of autoimmune diseases or as reagents for use in medicinal and pharmaceutical fields.
Inventor(s): Fujita; Tetsuro (Muko, JP), Sasaki; Shigeo (Kobe, JP), Yoneta; Masahiko (Kobe, JP), Mishina; Tadashi (Iruma, JP), Adachi; Kunitomo (Iruma, JP), Chiba; Kenji (Iruma, JP)
Assignee: Yoshitomi Pharmaceutical Industries, Ltd. (Osaka, JP) Taito Co., Ltd. (Tokyo, JP)
Application Number:08/244,942
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,604,229
Patent Claim Types:
see list of patent claims
Compound; Use;

Drugs Protected by US Patent 5,604,229

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis GILENYA fingolimod hydrochloride CAPSULE;ORAL 022527-001 Sep 21, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,604,229

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan4-283281Oct 21, 1992
Japan5-179427Jul 20, 1993
PCT Information
PCT FiledOctober 18, 1993PCT Application Number:PCT/JP93/01515
PCT Publication Date:April 28, 1994PCT Publication Number: WO94/08943

Non-Orange Book US Patents Family Members for Patent 5,604,229

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,719,176 2-amino-1,3-propanediol compound and immunosuppressant ➤ Try a Free Trial
5,952,316 2-amino-1,3-propanediol compound and immunosuppressant ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 5,604,229

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 172711 ➤ Try a Free Trial
Canada 2126337 ➤ Try a Free Trial
Cyprus 2215 ➤ Try a Free Trial
Germany 122011100012 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Cerilliant
Queensland Health
UBS
QuintilesIMS
Dow
Accenture
US Department of Justice
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.